Chinese expert consensus on the application of flow cytometry in the diagnosis and detection of minimal residual disease in B-cell non-Hodgkin lymphoma（2025）
TL;DR
This paper presents a Chinese expert consensus on using flow cytometry for diagnosing and monitoring B-cell non-Hodgkin lymphoma.
Contribution
It provides standardized guidelines for flow cytometry application in B-NHL diagnosis and minimal residual disease detection.
Findings
Flow cytometry is highlighted for its advantages in speed, sensitivity, and multi-parameter analysis.
The consensus covers sample preparation, immune phenotyping, result analysis, and quality control.
It aligns with updated WHO and ICC classifications for B-NHL subtypes.
Abstract
B细胞非霍奇金淋巴瘤（B-cell non-Hodgkin lymphoma，B-NHL）包含多种亚型，精准诊断依赖于多学科合作，包括病理形态学、免疫组织化学、流式细胞术（FCM）、细胞遗传学、分子生物学、影像学与临床特征等。FCM以其操作简单、快速、客观、灵敏度高和多参数分析等独特优势，在B-NHL的诊断和微小残留病（MRD）检测中发挥着不可替代的作用。随着第5版WHO造血与淋巴组织肿瘤分类和国际共识分类（ICC）的陆续发表，B-NHL中不同亚类的分型更加细化，一些分类方法和命名方式也发生了较大变化。为了提高B-NHL的诊断和治疗监测水平，规范我国对此类疾病的诊治程序，中国抗癌协会血液肿瘤专业委员会组织国内相关领域的专家经过多次讨论后，针对FCM在成熟B-NHL诊断和MRD检测中的应用，包括FCM样本来源与制备、不同亚型B-NHL免疫表型特点、结果分析与报告以及质量控制四方面制订了本专家共识。
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsLymphoma Diagnosis and Treatment